美股异动丨吉利德科学夜盘跌1.8%，今年产品销售额及盈利指引不及预期

Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Financial Performance - Q4 revenue increased to $7.9 billion, up from the previous year [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]